Review

Fecal microbiota transplantation beyond *Clostridioides difficile* infections

Koen Wortelboer a,*, Max Nieuwdorp b, c, d, Hilde Herrema a

a Department of Experimental Vascular Medicine, Amsterdam University Medical Center, Location Academic Medical Center, Amsterdam, the Netherlands
b Department of Vascular Medicine, Amsterdam University Medical Center, Location Academic Medical Center, Amsterdam, the Netherlands
c Department of Internal Medicine, Amsterdam University Medical Center, Location Academic Medical Center, Amsterdam, the Netherlands
d Amsterdam Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Center, Location VU University Medical Center, Amsterdam, the Netherlands

**A R T I C L E   I N F O**

Article history:
Received 17 January 2019
Received in revised form 31 May 2019
Accepted 31 May 2019
Available online 11 June 2019

**Keywords:**
Fecal microbiota transplantation
*Clostridioides difficile*
Inflammatory bowel disease
Irritable bowel syndrome
Metabolic syndrome
Cancer

**A B S T R A C T**

The importance of the commensal microbiota to human health and well-being has become increasingly evident over the past decades. From a therapeutic perspective, the popularity of fecal microbiota transplantation (FMT) to restore a disrupted microbiota and amend imbalances has increased. To date, most clinical experience with FMT originates from the treatment of recurrent or refractory *Clostridioides difficile* infections (rCDI), with resolution rates up to 90%. In addition to CDI, a role for the intestinal microbiome has been implicated in several disorders. FMT has been tested in several randomized controlled trials for the treatment of inflammatory bowel disease, irritable bowel syndrome and constipation with mixed results. FMT has also been explored for extra-gastrointestinal disorders such as metabolic syndrome, hepatic encephalopathy and graft-versus-host disease. With the exception of recurrent CDI, FMT is currently used in experimental settings only and should not yet be offered as standard care. In addition, it is critical to further standardize and optimize procedures for FMT preparation. This includes determination of active components of FMT to develop (personalized) approaches to treat disease.

© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

**Contents**

1. Introduction .......................................................... 717
2. *Clostridioides difficile* infection ..................................... 718
3. Gastrointestinal disorders ............................................. 718
   3.1. Inflammatory bowel disease ...................................... 718
   3.2. Ulcerative colitis .................................................. 718
   3.3. Crohn’s disease .................................................... 718
   3.4. Functional bowel disease ........................................ 719
   3.5. Antibiotic-resistant bacteria .................................... 719
4. Metabolic disorders ................................................... 720
   4.1. Metabolic syndrome .............................................. 720
   4.2. NAFLD and NASH ............................................... 720
   4.3. Cardiovascular disease ......................................... 720
5. Neuropsychiatric disorders .......................................... 721
   5.1. Hepatic encephalopathy ........................................ 721
   5.2. Autism spectrum disorder ...................................... 721
   5.3. Multiple sclerosis ............................................... 721
6. Parkinson’s disease .................................................. 721
7. Immunologic disorders ............................................... 721

**Abbreviations:** ACG, American College of Gastroenterology; ARBs, Antibiotic resistant bacteria; ASD, Autism spectrum disorders; CD, Crohn’s disease; CDI, *Clostridioides difficile* infection; CIPD, Chronic intestinal pseudo-obstruction; CRC, Colorectal cancer; CRE, Carbapenem-resistant Enterobacteriaceae; DJ, Duodenal/jejunal infusion; ESBL, Extended-spectrum beta-lactamase-producing; ESBL-E, Extended Spectrum Beta-Lactamase Enterobacteriaceae; ESCMID, European Society for Microbiology and Infectious disease; FMT, Fecal microbiota transplantation; GI, Gastrointestinal; GVHD, Graft-versus-host disease; HCT, Hematopoietic stem cell transplantation; HE, Hepatic encephalopathy; IBD, Inflammatory bowel disease; IBS, Irritable bowel syndrome; IBS-SSS, Irritable bowel syndrome severity scoring system; ICI, Immune checkpoint inhibitors; MS, Multiple sclerosis; NAFLD, Nonalcoholic fatty liver disease; NASH, Nonalcoholic steatohepatitis; PD, Parkinson’s disease; rCDI, Recurrent *Clostridioides difficile* infection; RCT, Randomized controlled trial; SAE, Serious adverse event; SCFA, Short-chain fatty acid; STC, Slow transit constipation; TMAO, Trimethylamine-N-Oxide; UC, Ulcerative colitis; VRE, Vancomycin-resistant Enterococci.

*Corresponding author.
E-mail address: k.wortelboer@amc.nl (K. Wortelboer).
1. Introduction

The human body harbors on average 10–100 trillion microbes, which is more than ten times the estimated number of human cells [1]. The majority of these microbial cells reside in the gastrointestinal (GI) tract and this complex community of microorganisms in the GI tract is termed the intestinal microbiota. The historical view that the gut microbiota is largely pathogenic has undergone a paradigm shift. Over the past few decades, the importance of the commensal microbiota to human health and well-being has become increasingly evident, as the impact of a healthy and diverse intestinal microbiota on metabolic activities, the immune system and homeostasis of the intestine has become more clear [2]. Furthermore, it has been shown that the gut microbiota influences the gut-brain axis, affecting brain function and development, and to confer colonization resistance against pathogenic bacteria [3,4].

Dysbiosis of the intestinal microbiota is defined as decreased bacterial diversity or a shift in bacterial species compared to a healthy control, e.g. a decrease in butyrate producers [5]. Many studies have shown that this dysbiosis is implicated in the development of a wide range of diseases (Fig. 1) [5,6]. However, for most diseases it is currently unknown whether the changes in microbiota are causally related to the pathophysiology or merely a consequence of the disease. For Clostridioides difficile infection (CDI), there is a clear causal relationship with disease
phenotype. For other diseases such as obesity and metabolic disease, a causal relationship still needs to be clarified [7]. In both scenarios, however, modulation of the intestinal microbiota to restore a balanced and diverse microbiota might hold merit to treat or prevent microbiome-related disease.

Fecal microbiota transplantation (FMT), also called “feces transplantation”, “human intestinal microbiota transfer” and “fecal bacteriotherapy”, is the transfer of the fecal microbiota from a healthy, screened donor to a recipient [8]. FMT aims to restore a disrupted microbiota and amend imbalances through establishment of a stable, complex microbiota. The earliest documented administration of a fecal suspension was by the traditional Chinese doctor Ge Hong in the 4th century [9]. He used so-called ‘yellow soup’ as a treatment for food poisoning and severe diarrhea. However, it wasn’t until the 16th century that another Chinese doctor named Li Shizhen recorded a range of fecal preparations for effective treatment of GI-diseases, such as constipation, fever, vomiting and pain. Subsequently during World War II, African Bedouins advised German soldiers stationed in Africa to consume fresh camel feces as a treatment for bacterial dysentery [10]. Although the potential health benefits of microbes were already mentioned by Metchnikoff in 1907, it wasn’t until 1958 that fecal enemas were first described for the treatment of pseudomembranous enterocolitis by Dr. Ben Eisenman, an American surgeon [11]. Thereafter, a plethora of articles on the potential of FMT to treat recurrent CDI (rCDI) have been written. In this review, the potential of FMT beyond treatment of CDI and the current evidence in support of FMT as a therapeutic approach will be discussed.

2. Clostridioides difficile infection

Currently, most clinical experience with FMT is derived from the treatment of CDI, in particular recurrent or refractory infections [12]. Over the past decades, the incidence of CDI has risen, while the success rate of prolonged anti-microbial therapy is low (20–30% resolution rate) [13]. FMT has emerged as an important treatment option for rCDI with high resolution rates (up to 90%) [13–15]. Over 100 case reports and clinical trials on the treatment of rCDI with FMT have been published to date; most report high resolution rates of C. difficile associated diarrhea. The first randomized controlled clinical trial (RCT) for FMT in CDI was performed in the Netherlands by Van Nood et al. In this study, authors observed a primary and cumulative resolution of 81% and 94% after one and two FMTs, respectively, compared to 31% after a vancomycin regimen [16].

Subsequently, the number of RCTs addressing the use of healthy donor (allogenic) FMT to treat rCDI has increased. In several publications, FMT via colonoscopy has been shown to be superior to fidaxomycin, vancomycin and autologous FMT [17–19]. The cumulative resolution rate after FMT via colonoscopy was over 90% compared to 42% for fidaxomycin, <30% for vancomycin and 63% for autologous FMT [17–19]. Comparison of nasogastric and colonoscopic administration of a freeze-thawed fecal suspension could not demonstrate a significant difference in resolution rate (both 90%), although the patient groups in this RCT were fairly small [20]. One RCT showed that freeze-thawed feces was as effective as fresh feces, both administered via enema, with resolution rates of 75% and 70% respectively [21]. In contrast, another RCT reported higher resolution rates with fresh FMT via colonoscopy compared to freeze-thawed and lyophilized FMT via colonoscopy, with resolution rates of 100%, 83% and 78%, respectively [22]. However, two RCTs found oral FMT capsules with either frozen or lyophilized fecal microbiota to be as effective as FMT via enema or colonoscopy, with resolution rates around 90% [23,24]. Recently, two small pilot RCTs evaluated the efficacy of FMT for primary CDI instead of rCDI with mixed results [25,26]. One study observed a higher primary resolution with FMT compared to metronidazole, while vancomycin performed better than FMT in the second study [25,26].

Several meta-analyses have confirmed the superiority of FMT over standard antibiotic treatment and indicated that FMT is a safe treatment for patients with rCDI [15,27,28]. In addition, colonoscopic delivery of FMT was associated with higher resolution rates, while duodenal infusion, enema and fecal amount < 50 g were associated with lower resolution rates [29]. Cost-effectiveness analyses have shown that FMT by colonoscopy (or enema, if colonoscopy is unavailable) is cost-effective, as the FMT procedure is relatively cheap and has a high efficacy [30,31]. The above findings have established FMT as an evidence-based treatment option for rCDI, which has been adopted by the European Society for Microbiology and Infectious disease (ESCMID) and the American College of Gastroenterology (ACG) (see Table 1) [32,33].

3. Gastrointestinal disorders

3.1. Inflammatory bowel disease

Inflammatory bowel disease (IBD) comprises ulcerative colitis (UC) and Crohn’s disease (CD). Both are characterized by recurring inflammation of the intestine. While UC is restricted to the large intestine, CD can affect the entire gastrointestinal tract. Both pathologies have been linked to dysbiosis of the gut microbiota, with a decreased diversity and decreases in Bacteroidetes and Firmicutes [34]. However, it remains unclear whether these shifts are a cause or a consequence of IBD. Some animal studies support a role for the gut microbiota in the pathogenesis of IBD, demonstrating that intestinal exposure to colitogenic microbiota induced spontaneous colitis [35]. Based on these findings, restoration of the gut microbiota through FMT has been explored as a treatment for IBD in several clinical trials.

3.2. Ulcerative colitis

Promising case reports and uncontrolled observational cohort studies have been published on the treatment of IBD with FMT, although the response rate to FMT is lower compared to rCDI. Of these studies, 53 were summarized in a systematic review, demonstrating clinical remission in 201/555 (36%) of UC, 42/83 (51%) of CD and 5/23 (22%) of pouchitis patients after FMT [36]. To date, four RCTs on the treatment of UC using FMT have been published, all showing promising results [34,37–39]. These results were pooled in a recent Cochrane meta-analysis, which demonstrated a significantly higher clinical remission at eight weeks in the FMT arm compared to the control arm, with 52/140 (37%) and 24/137 (18%) patients achieving remission, respectively [40]. Serious adverse events and adverse events did not significantly differ between groups. Importantly, methodology, FMT strategies and primary endpoints varied considerably among the RCTs. This exemplifies the necessity of additional dedicated studies.

Some studies indicated that the efficacy of a fecal transplant differed between transplant donors. These observations gave rise to the concept of super donors and highlight the importance of careful donor selection [37,38]. Furthermore, an enrichment in Eubacterium hallii and Roseburia inulivorans with increased levels of short-chain fatty acids and secondary bile acids was consistently found in patients in remission after FMT [41]. In addition, in patients that did not achieve remission, an enrichment in Fusobacterium goniodiformans, Sutterella wadsworthensis, and Escherichia species was observed, characterized by increased levels of heme and lipopolysaccharide biosynthesis.

3.3. Crohn’s disease

Evidence for FMT to treat CD is sparse and to date no RCTs have been published. In a meta-analysis of 11 uncontrolled observational cohort studies and case series in CD, 42/83 (51%) patients achieved clinical remission [36]. A prospective study observed clinical remission in 13/25 (52%) CD patients three months after FMT, which decreased to 5/22
(23%) 18 months after FMT [42]. Another study demonstrated that a second FMT, administered within 4 months after the first FMT, maintained the clinical benefits of the first FMT [43]. The largest prospective cohort study published to this day found a clinical remission in 79/139 (57%) patients one month after FMT [44]. However, the potential of FMT to treat CD is still uncertain and well-designed controlled studies addressing this question are needed. Compared to UC, CD is a more heterogeneous disease and it might be necessary to focus on specific disease phenotypes, instead of a general CD population.

3.4. Functional bowel disease

The efficacy of FMT is actively being explored in functional GI disorders, in particular irritable bowel syndrome (IBS) and chronic constipation. IBS is a chronic noninflammatory GI disorder, characterized by abdominal pain with diarrhea and/or constipation. Although the pathophysiology of IBS is not completely understood, several associations with the intestinal microbiota have been found. In line, this suggests a potential role for FMT to treat IBS [45,46]. Two RCTs were recently published showing conflicting results. In the first study, 36/55 (65%) patients in the FMT group had relief of IBS symptoms (≥75 points reduction on IBS severity scoring system (IBS-SSS)) three months after a single FMT via colonoscopy compared to 12/28 (43%) patients in the placebo group [47]. The second study reported a larger reduction in IBS-SSS (~125–71) in the placebo group (n = 23) after three months compared to the FMT group (n = 22) that received FMT-capsules for 12 days (~52–45) [48]. Although diversity of the microbiota increased in patients receiving FMT capsules, clinical improvement of IBS symptoms was not achieved. Discrepancies in study outcomes might originate from the different FMT administration strategies or the included IBS-subtypes. Results of several ongoing RCTs (see Fig. 2) will further disentangle the therapeutic potential of FMT to treat IBS.

The gut microbiota has also been implicated in the etiology of constipation. In one RCT, 60 adults with slow transit constipation (STC) received standard of care treatment (education, behavioral strategies, and oral laxatives) either with or without an additional 6 days FMT by nasoduodenal infusion [49]. After 12 weeks, clinical improvement was observed in 16/30 (53%) versus 6/30 (20%) patients and clinical cure (≥ three complete spontaneous bowel movements per week) in 11/30 (37%) versus 4/30 (13%) patients in the FMT and control group, respectively. Two prospective studies from the same group showed a decrease in clinical cure rate over time and observed higher efficacy of FMT in combination with the polysaccharide pectin in patients with STC [50,51]. A third prospective trial reported alleviation of bloating and pain symptoms in patients with chronic intestinal pseudo-obstruction (CIFO), a serious life-threatening motility disorder [52]. Although these results are promising, the FMT treatments were quite intense and invasive, with patients receiving up to 18 nasoduodenal FMTs over three months [51]. These limitations of dosing frequency and nasal tube placement could be addressed by using FMT capsules. Furthermore, the efficacy of the fecal microbiota in the FMT can be debated as the glycerol, used to protect the microbiota from freezing, could have a laxative effect.

3.5. Antibiotic-resistant bacteria

An increasing healthcare threat is intestinal colonization with multidrug-resistant organisms, which may cause life-threatening infections. Through direct ecological competition, FMT may potentially stimulate decolonization of antibiotic-resistant bacteria (ARBs) and increase resistance to colonization by these pathogens. This was first described in a case report where FMT was used for the successful eradication of an extended-spectrum beta-lactamase-producing (ESBL) Escherichia coli [53]. Thereafter, many case reports and small prospective cohort studies have been published, showing efficacy of FMT in decolonization of ESBL-producers, vancomycin-resistant Enterococcus (VRE), carbapenem-resistant Enterobacteriaceae (CRE) and other ARBs [54–57]. One open-label RCT has been published, which demonstrated decolonization of CRE or ESBL producers in 9/22 (41%) patients who received a five-day course of oral antibiotics followed by FMT compared to 5/17 (29%) patients who didn’t receive an intervention [58]. Interestingly, two prospective studies found a higher decolonization effect of FMT in the absence of periprocedural use of antibiotics, reporting decolonization in 6/7 (79%) and 7/8 (88%) patients after FMT [56,57]. Although the number of treated patients is small, these studies show that FMT might be an effective therapy for decolonization of antibiotic-resistant...
organisms from the GI-tract and more trials are currently under way to assess its safety and efficacy (see Fig. 2).

4. Metabolic disorders

4.1. Metabolic syndrome

There has been an increasing interest in the role of the gut microbiota in metabolic diseases, as microbes play a crucial role in digestion and absorption of nutrients from the diet. Furthermore, gut bacteria produce metabolites with critical properties for host metabolism including -but not limited to- short-chain fatty acids (SCFA) and bile acids. Dysbiosis of the intestinal microbiota has been linked to an impaired mucosal barrier function, also known as a “leaky gut”, a proinflammatory state and a disturbed production of signaling molecules, such as SCFAs and bile acids [59]. Animal studies suggest a causal link between the intestinal microbiota and obesity. For example, mice colonized with obesogenic microbiota were shown to have increased body fat and insulin resistance compared to mice colonized with lean donor microbiota [60]. Currently, two placebo-controlled RCTs have been published, which determined the effect of nasoduodenal FMT in obese Caucasian males with metabolic syndrome [61,62]. Six weeks after nasoduodenal infusion of lean donor feces, insulin sensitivity was significantly increased. This coincided with an increase in butyrate-producing intestinal microbiota. Importantly, the effect on insulin sensitivity disappeared after 18 weeks and no long-term clinical effects were found. In addition, metabolic response to FMT was found to be associated with a low microbial diversity at baseline [62]. Although the mechanisms underlying the favorable effects on insulin sensitivity are yet to be determined, these studies highlight a role for the intestinal microbiota in metabolic diseases.

4.2. NAFLD and NASH

Nonalcoholic fatty liver disease (NAFLD) is characterized by accumulation of fat in the liver, which may lead to inflammation and liver damage, commonly known as nonalcoholic steatohepatitis (NASH). NASH is a major cause of liver cirrhosis and liver cancer; both primary indications for liver transplantation. Differences in microbiota composition have been observed in patients with NAFLD or NASH compared to subjects with healthy liver [59]. In addition, increased intestinal permeability and a proinflammatory environment in the gut are frequently observed in NAFLD/NASH patients [63]. Although human studies are yet to be performed, studies in high-fat diet-fed mice found that FMT reduced weight gain and nonalcoholic fatty liver score [64]. To further investigate the potential of FMT in NASH there are several RCTs underway (summarized in Fig. 2), determining the efficacy of FMT compared to standard therapy in NASH related cirrhosis.

4.3. Cardiovascular disease

Accumulating evidence has implicated a role of the intestinal microbiota and microbial metabolites in the development of cardiovascular disease such as atherosclerosis and hypertension [65]. In an animal model, the introduction of a proinflammatory microbiota low in SCFA-producers enhanced systemic inflammation and accelerated atherogenesis [66]. In another study, mice with myocarditis were subjected to FMT. This resulted in reshaping of the microbiota composition and
restoration of the Bacteroidetes population, which was accompanied by attenuation of myocarditis through reduced inflammatory infiltration of immune cells [67]. Currently, one small RCT in humans has addressed the effect of a single lean vegan-donor FMT on vascular inflammation and trimethylamine-N-Oxide (TMAO) production. TMAO is a microbial metabolite which increases atherosclerotic burden and stimulates a prothrombotic phenotype [68]. Although SCFA-producers were significantly enriched in the allogenic FMT group, no differences were detected in TMAO production or vascular inflammation at two weeks.

5. Neuropsychiatric disorders

5.1. Hepatic encephalopathy

Hepatic encephalopathy (HE) comprises a spectrum of neuropsychiatric abnormalities as a result of end-stage liver cirrhosis. HE has been associated with differences in the microbiota and an increased relative abundance of ammonia-producing bacteria [69]. Subsequent hyperammonemia is associated with impaired neuronal function [69]. Current treatment strategies for HE consist of lactulose supplementation and treatment with the nonabsorbable antibiotic rifaximin, which both influence the intestinal microbiota. Currently, one RCT has been published in which patients with HE were treated with a single FMT via enema in addition to standard of care treatment [70]. Fewer serious adverse events (2 versus 8) and new episodes of HE (0 versus 6) were observed in the FMT arm (n = 10) compared to the control group (n = 10) receiving solely standard of care. Furthermore, cognition and dysbiosis improved after FMT. In a small pilot study, eight patients with steroid-ineligible severe alcoholic hepatitis were treated with a nasoduodenal FMT for seven days [71]. Liver disease severity reduced and coincided with resolution of ascites and HE. Moreover, survival rate improved compared to historically matched controls. These studies show promising results and multiple clinical studies addressing the use of FMT in HE are underway (see Fig. 2).

5.2. Autism spectrum disorder

Autism spectrum disorders (ASD) are not only characterized by impairments in social interaction and communication, but often coincide with GI symptoms such as constipation or diarrhea [72]. Experiments in ASD mouse models have mechanistically linked the gut microbiota to abnormal metabolites and behavior [73]. To this day, one open-label study has explored the effect of FMT on GI and ASD symptoms in children aged 7–16 years [74]. 18 children were placed on a two-week antibiotic regimen, a bowel lavage and either an initial rectal or oral high FMT dose, followed by a daily lower oral maintenance dose for 7–8 weeks. After FMT, both GI and ASD symptoms significantly improved, which persisted for 8 weeks after treatment. These are promising results, although the potential causal contributions of the gut microbiota to ASD remain speculative.

5.3. Multiple sclerosis

A number of studies have shown intestinal microbiota dysbiosis in patients with multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system [75]. Additionally, animal models have shown that feces from patients with MS could precipitate an MS-like autoimmune disease in mice, which suggests microbiota involvement in the pathogenesis of MS. [76] Some case reports describe improvement of neurological symptoms and disease stability after FMT, although more research is needed to determine the benefit and safety of FMT in MS. [77,78]

6. Parkinson's disease

Also for Parkinson's disease (PD) intestinal dysbiosis has been reported, with decreases in Prevotella and butyrate-producing bacteria [79]. An observational study found a decrease in total count of gut microbiota during PD progression and changes in gut microbiota could be correlated with a rapid or slow disease progression [79]. In a mouse model, gut microbiota transplantation from donor mice with PD reduced striatal neurotransmitter release with subsequent motor impairment in healthy recipient mice [80]. Furthermore, healthy mouse donor FMT had neuroprotective effects in PD mice through suppression of neuroinflammation and reduction of TLR4/TNF-α signaling [80]. FMT could have a potential benefit in PD, but studies in humans have not been performed yet.

7. Immunologic disorders

7.1. Graft-versus-host disease

Acute intestinal graft-versus-host disease (GVHD) is a major cause of mortality in patients that receive an allogenic hematopoietic stem cell transplantation (HCT). Standard treatment consists of immunosuppressive steroids, although some patients develop steroid-refractory GVHD for which no well-established treatment is available. Growing evidence suggests that the risk of GVHD is influenced by host-microbiota interactions and one study observed an increased mortality in recipients with a lower phylogenetic diversity [81]. In a mouse model, alterations in intestinal microbiota following HCT resulted in a decreased butyrate production, potentially contributing to a proinflammatory state of the intestine [82]. Results from several case series on FMT to treat acute steroid-refractory GVHD have shown some promise, demonstrating resolution of clinical symptoms, restoration of microbiota composition and a higher progression-free survival [83–85]. In a recent prospective open-label study, 13 patients were treated with FMT capsules to restore their intestinal microbiome diversity at a median of 27 days after HCT [86]. During a median follow-up period of 15 months after FMT, two patients developed acute GI GVHD which resulted in one death. The 12-month overall survival and progression-free survival were both 85%. Although the results of FMT in GVHD are promising, larger controlled studies are needed.

7.2. Cancer

Microbial dysbiosis has been extensively observed in human malignancies [87]. Several bacterial species are linked to colorectal cancer (CRC), including Enterococcus faecalis, Escherichia coli and Bacteroides fragilis [88]. This finding was supported by animal studies, in which the infusion of feces from patients with CRC could promote tumorigenesis in germ-free mice [89]. Although FMT has not been tested as a treatment for CRC, it has been used to increase the efficacy of immune checkpoint inhibitors (ICI). Only a minority of patients with CRC responds to ICIs, which has been linked to an abnormal gut microbiome composition [90]. Moreover, it has been shown that antibiotics inhibit the clinical benefit of ICIs [90]. It has been hypothesized that restoration of the microbiome reinforces the intestinal barrier integrity and reduces systemic inflammation [90]. When the feces from cancer patients who responded to ICIs was transplanted into germ-free mice, the antitumor effects of ICIs were ameliorated, whereas feces from non-responders failed to do so [90]. In one case-series, FMT was used to successfully treat refractory ICI-associated colitis, reconstitute the GI microbiome and increase the proportion of regulatory T-cells in the colonic mucosa [91]. These results indicate the important role of the microbiota in ICI-related toxicity and efficacy and point to a potential role for microbiota-modifying therapies, such as FMT. A recently published review by Wardill et al. extensively describes the use of FMT in supportive oncology more into depth [92].
Table 2
Ongoing trials with fecal microbiota transplantation for indications other than CDI.

| Indication         | NCT number                          | Intervention                                                                 | Study design                                              | Primary outcome                                                                                           | Patients (n) |
|--------------------|-------------------------------------|------------------------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|--------------|
| IBD                | NCT03399188                         | I: FMT via colonoscopy                                                      | Single group, open label trial                            | - Clinical remission (PUCAI / Mayo score / PCDAI / CDAI) [6 months]                                         | 100          |
|                    | NCT02575040                         | I: FMT                                                                       | Single group, open label trial                            | - number of patients with worsened disease [1 year]                                                        | 60           |
| Ulcerative colitis | NCT01790061                         | I: FMT via DJ C: standard of care treatment                                 | Controlled, open label trial                              | - Safety: (serious) adverse events [1 year]                                                               | 500          |
|                    | NCT03843385                         | I: fecal microbiota filtrate capsules II: FMT capsules C: placebo capsules   | 3- arm, randomized, placebo-controlled, quadruple blinded trial | - Clinical remission (Mayo score) [12 weeks]                                                             | 174          |
|                    | NCT03483246                         | I: FMT via colonoscopy C: sham via colonoscopy                               | Randomized, placebo-controlled, single blinded trial     | - Steroid-free clinical and endoscopic remission [12 weeks]                                              | 150          |
|                    | NCT03804931                         | I: FMT C: Saline                                                            | Randomized, placebo-controlled, single blinded trial     | - Clinical remission (Mayo score) [12 weeks]                                                             | 120          |
|                    | NCT03110289                         | I: super donor FMT C: autologous FMT                                        | Randomized, controlled, quadruple blinded trial          | - Clinical remission (Mayo score) [8 weeks]                                                              | 108          |
|                    | NCT02291523                         | I: allogenic FMT via colonoscopy C: autologous FMT via colonoscopy C: FMT capsules | Randomized, controlled, quadruple blinded trial          | - Endoscopic remission [8 weeks]                                                                        | 101          |
|                    | NCT03582969                         | I: FMT capsules C: placebo capsules                                        | Randomized, placebo-controlled, triple blinded trial | - Clinical remission (SCCAI) [12 weeks]                                                                 | 100          |
|                    | NCT03561532                         | I: allogenic FMT via colonoscopy C: autologous FMT via colonoscopy C: FMT capsules | Randomized, controlled, quadruple blinded trial          | - Clinical and endoscopic remission [52 weeks]                                                          | 80           |
|                    | NCT02606032                         | I: FMT + metronidazole + doxycycline + terbinfine C: FMT                      | Randomized, controlled, quadruple blinded trial          | - Clinical and endoscopic remission [9 weeks]                                                            | 80           |
|                    | NCT0316780                         | I: FMT C: Saline                                                            | Randomized, placebo-controlled, open label trial         | - Safety: (serious) adverse events [3 months]                                                           | 60           |
| Crohn’s disease    | NCT03104036                         | I: FMT via enema C: mesalazine enema                                        | Randomized, controlled, open label trial                  | - Clinical remission (Mayo score) [12 weeks]                                                             | 60           |
|                    | NCT0300689                          | I: antibiotics + FMT via colonoscopy + FMT capsules II: FMT via colonoscopy C: autologous FMT via colonoscopy | 4-arm, randomized, controlled, open label trial         | - Safety: (serious) adverse events [1 year]                                                             | 40           |
|                    | NCT02734589                         | I: FMT via colonoscopy II: diet for UC + FMT III: diet for UC                  | 3-arm, randomized, controlled, single blinded trial      | - Clinical remission (SCCAI) [56 days]                                                                  | 34           |
|                    | NCT03948919                         | I: low sulfur FMT capsules C: placebo capsules                               | Randomized, placebo-controlled, quadruple blinded trial | - Engraftment of sulfate reducing microbiota [12 weeks]                                                  | 20           |
|                    | NCT02390726                         | I: FMT C: placebo FMT                                                        | Randomized, placebo-controlled, double blinded trial    | - Endoscopic stage [2 years]                                                                            | 20           |
|                    | NCT03949257                         | I: FMT via DJ                                                               | Single group, open label trial                           | - Biologic inflammatory markers [2 years]                                                                | 20           |
|                    | NCT03716388                         | I: FMT + mesalazine granules II: FMT + placebo granules III: mesalazine granules + placebo FMT | 3-arm randomized, controlled, double blinded trial | - Symptomatology and quality of life [2 years]                                                          | 20           |
|                    | NCT01793831                         | I: FMT via DJ                                                               | Single group, open label trial                           | - Gut microbiome [7 days]                                                                                 | 20           |
|                    | NCT03078803                         | I: FMT via colonoscopy and capsules C: water via colonoscopy and placebo capsules | Randomized, placebo-controlled, quadruple blinded trial | - Clinical remission (HBI score) [1 year]                                                               | 200          |
|                    | NCT03378167                         | I: FMT via colonoscopy + FMT capsules C: Placebo FMT                        | Randomized, placebo-controlled, triple blinded, crossover trial | - Clinical and endoscopic remission [8 weeks]                                                            | 126          |
|                    | NCT02417974                         | I: FMT via colonoscopy C: no intervention                                    | Randomized, controlled, single blinded trial             | - Monthly Recruitment Rate [30 weeks]                                                                   | 45           |
|                    | NCT03267238                         | I: FMT                                                                       | Single group, open label trial                           | - Dropout Rate Post Enrolment [30 weeks]                                                                | 44           |
|                    | NCT03747718                         | I: FMT via enema C: placebo via enema                                        | Randomized, placebo-controlled, triple blinded trial   | - Rate of Patient Protocol Adherence [30 weeks]                                                          | 40           |
|                    | NCT03194529                         | I: FMT via DJ                                                               | Single group, open label trial                           | - Safety: (serious) adverse events [6 months]                                                            | 30           |
| Pouchitis          | NCT03524352                         | I: FMT C: sterile saline                                                     | Randomized, placebo-controlled, double blinded trial    | - Safety: (serious) adverse events [24 weeks]                                                            | 10           |
|                    | NCT03545386                         | I: FMT via enema                                                            | Randomized, placebo-controlled, double blinded trial    | - Clinical and endoscopic relapse (PDAI) [106 weeks]                                                    | 42           |
| Indication                      | NCT number          | Intervention                                      | Study design                                      | Primary outcome                                                      | Patients (n) |
|--------------------------------|---------------------|--------------------------------------------------|--------------------------------------------------|---------------------------------------------------------------------|--------------|
| IBS                            | NCT03125564         | I: FMT                                             | Randomized, placebo-controlled, single blinded trial | - Proportion of responder [12 weeks]                                | 90           |
|                                |                     | C: placebo FMT                                    |                                                   |                                                                     |              |
|                                | NCT02847481         | I: FMT                                             | Randomized, placebo-controlled, double blinded trial | - Engraftment of donor microbiota [10 weeks]                        | 80           |
|                                |                     | C: placebo FMT                                    |                                                   |                                                                     |              |
|                                | NCT03205757         | I: Anaerobic cultured human intestinal microbiota | Single group, open label trial                   | - Symptom relief (IBS-SSS) [4 weeks]                               | 50           |
|                                |                     |                                                   |                                                   |                                                                     |              |
|                                | NCT03074227         | I: allogenic FMT via DJ                           | Randomized, controlled, quadruple blinded trial   | - >50% reduction in severity and frequency of abdominal pain [12 weeks] | 30           |
|                                |                     | C: no intervention                                |                                                   |                                                                     |              |
|                                | NCT025812020        | I: allogenic FMT via DJ                           | Randomized, controlled, quadruple blinded trial   | - Symptoms of IBS patients (GSRS-IBS) [6 months]                    | 17           |
|                                |                     | C: no intervention                                |                                                   |                                                                     |              |
|                                | NCT02851740         | I: Rifaximin 400 mg + FMT via DJ                   | Single group, open label trial                   | - Relief of IBS condition [5 months]                               | 10           |
|                                |                     |                                                   |                                                   |                                                                     |              |
| Chronic constipation            | NCT03018613         | I: FMT                                             | Randomized, placebo-controlled, open label trial  | - Safety: (serious) adverse events [3 months]                       | 60           |
|                                |                     | C: Saline                                          |                                                   |                                                                     |              |
| Antibiotic resistant           | NCT03061097         | I: allogenic FMT via enema                         | Randomized, placebo-controlled, triple blinded trial | - Safety: (serious) adverse events [7 days]                         | 180          |
| organisms                      |                     | C: placebo via enema                               |                                                   |                                                                     |              |
|                                | NCT03643887         | I: FMT capsules                                    | Randomized, placebo-controlled, triple blinded trial | - VRE/CRE decolonization [6 months]                                | 90           |
|                                |                     | C: placebo capsules                                |                                                   |                                                                     |              |
|                                | NCT03391674         | I: FMT capsules + omeprazole                       | Randomized, controlled, open label trial         | - CRE Decolonization (3 consecutive negative stool samples for CRE) [3 months] | 60           |
|                                |                     | C: no intervention                                |                                                   |                                                                     |              |
|                                | NCT03167398         | I: FMT capsules + omeprazole                       | Single group, open label trial                   | - CRE Decolonization (3 consecutive negative stool samples for CRE) [1 month] | 60           |
|                                |                     |                                                   |                                                   |                                                                     |              |
|                                | NCT03840641         | I: FMT via enema                                    | Single group, open label trial                   | - Clearance of antimicrobial resistant organism [2 years]            | 50           |
|                                |                     |                                                   |                                                   |                                                                     |              |
|                                | NCT03029078         | I: FMT via DJ                                       | Single group, open label trial                   | - Intestinal colonization with CRE/VRE [6 months]                   | 50           |
|                                |                     |                                                   |                                                   |                                                                     |              |
|                                | NCT03802461         | I: FMT via enema                                    | Randomized, controlled, open label trial         | - Intestinal colonization with CRE [3 months]                        | 40           |
|                                |                     | C: standard of care treatment                      |                                                   | - Feasibility: randomization rate [12 months]                       |              |
|                                |                     |                                                   |                                                   | - Feasibility: retention of 90% of patients [6 months]              |              |
|                                | NCT03479710         | I: FMT via DJ                                       | Controlled, open label trial                     | - Intestinal colonization with CRE/VRE [12 months]                  | 40           |
|                                |                     |                                                   |                                                   |                                                                     |              |
|                                | NCT02472600         | I: colistin + peonycin, followed by FMT capsules or ND infusion | Randomized, controlled, open label trial | - Intestinal colonization with ESBL-E / CRE [48 days] | 39           |
|                                |                     | C: no intervention                                |                                                   |                                                                     |              |
|                                | NCT02922816         | I: FMT via enema                                    | Randomized, controlled, open label trial         | - Safety and feasibility (CTCAE v4.0) [30 weeks]                    | 20           |
|                                |                     | C: no intervention                                |                                                   |                                                                     |              |
|                                | NCT03527056         | I: FMT capsules                                    | Controlled, open label trial                     | - CRE decolonization [10 days]                                     | 20           |
|                                |                     | C: no intervention                                |                                                   | - Safety: (serious) adverse events [10 days]                       |              |
|                                | NCT02453866         | I: FMT via DJ                                       | Single group, open label trial                   | - Safety and Tolerability of FMT [1–5 years]                        | 20           |
|                                |                     |                                                   |                                                   |                                                                     |              |
|                                | NCT02312986         | I: FMT via enema                                    | Single group, open label trial                   | - Safety: (serious) adverse events [12 months]                      | 20           |
|                                |                     |                                                   |                                                   |                                                                     |              |
|                                | NCT02816437         | I: FMT via enema                                    | Single group, open label trial                   | - Safety: (serious) adverse events [10 days]                        | 20           |
|                                |                     |                                                   |                                                   |                                                                     |              |
|                                | NCT03063437         | I: FMT capsules                                    | Randomized, placebo-controlled, quadruple blinded trial | - VRE decolonization [10 days]                                     | 9            |
|                                |                     | C: placebo capsules                                |                                                   | - Safety: (serious) adverse events [10 days]                       |              |
| Obesity                       | NCT03727321*        | I: FMT + fiber supplement                          | 4-arm, randomized, placebo-controlled, quadruple blinded trial | - Insulin resistance (HOMA-IR) [12 weeks]                           | 68           |
|                                |                     | II: FMT + placebo supplement                       |                                                   |                                                                     |              |
|                                |                     | III: fiber supplement                              |                                                   |                                                                     |              |
|                                |                     | C: placebo supplement                              |                                                   |                                                                     |              |
|                                | NCT03127896         | I: FMT + lifestyle modification program            | 3-arm randomized, placebo-controlled, double blinded trial | - %5 reduction in weight [24 weeks]                                | 60           |
|                                |                     | II: FMT                                             |                                                   |                                                                     |              |
|                                |                     | III: lifestyle modification program                 |                                                   |                                                                     |              |
|                                |                     | C: placebo supplement                              |                                                   |                                                                     |              |
|                                | NCT0273855          | I: allogenic FMT via enema                          | Randomized, controlled, quadruple blinded trial   | - Changes in body weight [12 months]                               | 60           |
|                                |                     | C: no intervention                                |                                                   |                                                                     |              |
|                                | NCT02970877         | I: allogenic FMT                                   | Randomized, controlled, quadruple blinded trial   | - Insulin Resistance (HOMA-IR) [3 months]                           | 48           |
|                                |                     | C: allogenic FMT                                   |                                                   |                                                                     |              |
|                                | NCT03391817         | I: allogenic FMT                                   | Randomized, controlled, triple blinded trial      | - Reduction of weight [1.5 years]                                   | 40           |
|                                |                     | C: allogenic FMT                                   |                                                   |                                                                     |              |

*(continued on next page)*
| Indication                                           | NCT number                  | Intervention                                                                 | Study design                                                                 | Primary outcome                                                                 | Patients [n] |
|-----------------------------------------------------|-----------------------------|-----------------------------------------------------------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------|
| Acute Pancreatitis                                  | NCT02530385                 | I: FMT capsules C: placebo capsules                                          | Randomized, placebo-controlled, double blinded trial                         | - Insulin resistance (HOMA-IR) [6 weeks]                                      | 24           |
|                                                     | NCT02741518                 | I: FMT capsules C: placebo capsules                                          | Randomized, placebo-controlled, triple blinded trial                         | - Safety: (serious) adverse events [52 weeks]                                  | 22           |
|                                                     | NCT03789461                 | I: FMT                                                                       | Single group, open label trial                                               | - 10% reduction in weight [6 weeks]                                           | 20           |
| NAFLD                                               | NCT02868164                 | I: FMT via DJ C: standard of care treatment                                  | Randomized, controlled, open label trial                                     | - Adverse events complication rate in NASH [1 year]                             | 120          |
|                                                     | NCT02721264                 | I: FMT via DJ C: standard of care treatment                                  | Randomized, controlled, open label trial                                     | - Hepatic Venous Pressure Gradient [1 year]                                    | 112          |
|                                                     | NCT03803540                 | I: FMT via DJ                                                                | Single group, open label trial                                               | - Histological resolution of NASH [72 weeks]                                   | 15           |
|                                                     | NCT02469272                 | I: FMT via DJ                                                                | Single group, open label trial                                               | - Hepatic steatosis (by MRI) [12 weeks]                                       | 5            |
| Alcoholic hepatitis                                  | NCT03091010                 | I: FMT via DJ C: prednisolone 40 mg                                          | Randomized, controlled, open label trial                                     | - Overall Survival [3 months]                                                 | 130          |
|                                                     | NCT03827772                 | I: FMT via DJ C: standard of care treatment                                  | Controlled, open label trial                                                | - Overall Survival [3 months]                                                 | 40           |
| Liver cirrhosis & hepatic encephalopathy            | NCT03796598                 | I: FMT capsules + placebo enema II: placebo capsules + FMT enema III: placebo capsules + placebo enema | 4-arm, randomized, placebo-controlled, triple blinded trial | - Serious adverse events related to FMT [6 months]                             | 100          |
|                                                     | NCT03363022                 | I: FMT via enema C: placebo via enema                                         | Randomized, placebo-controlled, double blinded trial                         | - Survival [21 days]                                                          | 40           |
|                                                     | NCT02862249                 | I: FMT via DJ C: placebo via DJ                                             | Randomized, placebo-controlled, single blinded trial                         | - Feasibility of FMT [18 months]                                              | 32           |
|                                                     | NCT03439982                 | I: FMT via colonoscopy + FMT via enema                                       | Single group, open label trial                                               | - Safety: (serious) adverse events [18 months]                                | 30           |
|                                                     | NCT03420482                 | I: FMT capsules C: placebo capsules                                          | Randomized, placebo-controlled, quadruple blinded trial                     | - Time to hepatic encephalopathy breakthrough [9 weeks]                         | 30           |
|                                                     | NCT03416751                 | I: FMT via enema C: saline via enema                                         | Randomized, placebo-controlled, double blinded trial                         | - Psychometric Hepatic Encephalopathy Score [28 days]                          | 20           |
|                                                     | NCT02255617                 | I: FMT via colonoscopy and enema                                            | Single group, open label trial                                               | - Safety: (serious) adverse events [15 days]                                   | 20           |
| Acute Pancreatitis                                  | NCT03015467                 | I: FMT C: Saline                                                             | Randomized, placebo-controlled, open label trial                            | - Related transmissible infectious disease [15 days]                           | 10           |
|                                                     | NCT02318134                 | I: FMT via enema + traditional treatment C: traditional treatment           | Randomized, controlled, single blinded trial                                | - Tolerability: GI distress Post FMT [3 years]                                | 80           |
|                                                     | NCT02318147                 | I: FMT via enema + traditional treatment C: traditional treatment           | Randomized, controlled, single blinded trial                                | - Gastrointestinal Failure score [7–14 days]                                  | 60           |
| Severe acute malnutrition                           | NCT03087097                 | I: FMT via enema C: placebo via enema                                        | Randomized, placebo-controlled, quadruple blinded trial                     | - Control of infectious complications [from admission to discharge]            | 60           |
| Anorexia Nervosa                                     | NCT03928808                 | I: FMT via DJ                                                                | Single group, open label trial                                               | - Safety: serious adverse events [56 days]                                    | 20           |
| Graft Versus Host Disease                           | NCT03862079                 | I: total gut decontamination + FMT via enema II: FMT via enema III: standard of care treatment | 3-arm, randomized, controlled, open label trial                            | - Tolerability: GI distress Post FMT [3 years]                                | 10           |
|                                                     | NCT03678493                 | I: FMT capsules C: placebo capsules                                          | Randomized, placebo-controlled, open label trial                            | - Tolerance: development of acute GVHD [100 days]                             | 120          |
|                                                     | NCT03492502                 | I: autologous FMT via DJ                                                     | Single group, open label trial                                               | - Relapse-free survival [6 months]                                            | 60           |
|                                                     | NCT03720392                 | I: FMT capsules C: placebo capsules                                          | Randomized, placebo-controlled, double blinded trial                         | - Incidence of infections [4 months]                                          | 120          |
|                                                     | NCT03359980                 | I: FMT                                                                       | Single group, open label trial                                               | - Safety: (serious) adverse events [7 days]                                   | 70           |
|                                                     | NCT03812705                 | I: FMT via colonoscopy of ND tube                                            | Single group, open label trial                                               | - Gut microbiome diversity [1 month]                                           | 48           |
|                                                     | NCT03549676                 | I: FMT via DJ                                                                | Single group, open label trial                                               | - GI and overall GVHD response [28 days]                                      | 32           |
|                                                     |                             |                                                                             |                                                                              | - Response rate [12 weeks]                                                    | 30           |
Table 2 (continued)

| Indication                | NCT number       | Intervention                                    | Study design                                                                 | Primary outcome                                                                 | Patients (n) |
|---------------------------|------------------|------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------|-------------|
| Depression                | NCT03766321      | I: FMT via colonoscopy                          | Single group, open label trial                                               | 7 and 28. - GI-GVHD remission [90 days]                                          | 40          |
|                           |                  | C: sham FMT via DJ                              |                                                                               |                                                                                |             |
|                           | NCT03233100      | I: FMT                                          | Single group, open label trial                                               | - Complete spontaneous bowel movements [12 weeks]                               | 40          |
|                           |                  | C: placebo capsules                             |                                                                               | - Anxiety symptoms [HAMA] [12 weeks]                                            |             |
|                           |                  |                                                |                                                                               | - Depressive symptoms [HAMD] [12 weeks]                                          |             |
|                           | NCT03408886      | I: FMT capsules                                 | Single group, open label trial                                               | - Anxiety symptoms [CARS] [10 weeks]                                            | 84          |
|                           |                  |                                                |                                                                               |                                                                                |             |
|                           | NCT03426826      | I: FMT via DJ                                   | Single group, open label trial                                               | - Safety and tolerability [24 weeks]                                            | 10          |
|                           |                  | C: placebo via DJ                               |                                                                               | - Symptom changes [RBS-R] [24 weeks]                                            |             |
|                           | NCT03691987      | I: allogenic FMT via colonoscopy                | Single group, open label trial                                               | - Clinical response [FSS] [3 months]                                            | 80          |
|                           |                  | C: autologous FMT via colonoscopy               |                                                                               |                                                                                |             |
|                           | NCT02889627      | I: FMT via DJ                                   | Single group, open label trial                                               | - Frequency of the seizures [3 months]                                          | 50          |
|                           |                  | C: placebo via DJ                               |                                                                               |                                                                                |             |

The above table summarizes ongoing trials studying the effect of FMT for a variety of diseases. Studies are grouped in ‘gastrointestinal’, ‘metabolic’, ‘immunologic’ and ‘neuropsychiatric’ disorders, sorted by disease and number of included patients. These studies were derived from Clinicaltrial.gov in May 2019. Ongoing trials were included when they were registered as ‘Active’, ‘recruiting’, ‘enrolling via invitation’ or ‘not yet recruiting’. Only intervention studies were included. In addition, studies examining the effect of FMT in treating CDI were excluded, since this is out of the scope of this review. There were several methods for upper administration of FMT (i.e. gastroscopy, nasoduodenal tube, transendoscopic enteral tube, etc.), which were pooled for simplicity as duodenal/jejunal infusion (D/J). Within brackets, the time frame of a primary outcome can be found. Abbreviations: I = intervention, C = control, FMT = fecal microbiota transplantation, D/J = duodenal/jejunal infusion, IBD = Inflammatory Bowel Disease, UC = Ulcerative Colitis, IBS = Irritable Bowel Syndrome, CRE = Carbenenit-Resistant Enterobacteriaceae, VRE = Vancomycin-Resistant Enterococci, ESBL-E = Extended Spectrum Beta-Lactamae Enterobacteriaceae, NAFLD = Non-Alcoholic Fatty Liver Disease, NASH = Non-Alcoholic Steatohepatitis, GI = Gastrointestinal, GVHD = Graft Versus Host Disease.

* Entry NCT03582969 was the same as NCT03273465, which were therefore merged. The same goes for entry NCT03477916, which was the same as NCT03727321.
8. Discussion & conclusion

Interest in FMT to treat disease has risen over the last few years and its therapeutic benefit is currently being explored for a variety of diseases. Table 1 provides an overview of the current and potential indications for FMT. Besides the above described disorders, the use of FMT has been described in case reports as treatment for multiple organ dysfunction syndrome, chronic pouchitis and celiac disease [93–95]. However, for most diseases it is not fully known whether the changes in microbiota are causally related to the pathophysiology, or merely a result of the disorder. If the intestinal microbiota plays a causal role in disease pathophysiology, altering the microbiota may influence its course. In most cases, however, a single microorganism is not likely to be a causal pathogen or missing beneficial microbiota. Therefore, an advantage of FMT over prebiotics and probiotics is the introduction of a complete healthy gut microbiota. FMT can be used as a tool to disentangle association from causality in human intervention studies by assessing the effect of the microbiota on a disease. Fig. 2 and Table 2 give an overview of currently ongoing clinical trials that study the potential of FMT as a treatment for a variety of disorders.

Currently, FMT is a non-standardized treatment which should be optimized and standardized for specific indications. This is supported by the finding of super donors, which suggests a specific bacterial composition can be more effective to treat a certain disease [37,38]. In addition, treatment strategy and route can impact the microbiota composition and colonization, which can influence the therapeutic effect. With the development of FMT capsules, the therapy became less invasive, more standardized, and less expensive [96]. However, some microbes (or metabolites) critical for the efficacy of an FMT might not survive the processing required for capsulation. Therefore, it is important to determine the differences between fresh and processed fecal microbiota and the efficacy in particular diseases. Furthermore, optimal location of delivery and ‘dose’ of FMT to treat microbiota-mediated diseases are largely unknown. A small cohort study showed that capsules releasing fecal microbiota in the colon achieved a slightly higher cure rate (81%) compared to gastric release (75%) in treating patients with rCDI [97]. Delivery of microbiota to a specific area of the intestine via targeted opening of a capsule might be an interesting future approach to further investigate.

Given the variable composition of feces, FMT will probably be replaced by other microbiome-targeting therapeutics. While the knowledge of the microbiota and host-commensal interactions in dysbiotic environments increases, it is to be expected that dietary manipulation and specific alteration of key microbes will be emerging in the future. Furthermore, it appears FMT is not a one-size-fits-all therapy and needs a more personalized approach for several disorders. For instance, donors with a specific microbiota profile are more likely to provide a beneficial effect for patients with IBD [37,38]. Other studies have shown that the microbiota profile of the recipient is predictive for the outcome of the FMT [62]. Future studies should therefore focus more on donor-recipient compatibility and suitability prior to FMT.

With the rapid increase in novel and more affordable techniques to analyze the gut microbiota, implications for a role of this ‘endocrine organ’ in disease development has risen exponentially. It is important to emphasize however, that besides bacteria, the microbiota consists of archaea, viruses (especially bacteriophages) and fungi. Bacteriophages, viruses that specifically infect and eliminate bacteria, were found to be 20 times more abundant than bacteria in mucosal samples [98]. Given the high number of bacteriophages in an FMT (1–10 times the number of bacteria), these viruses might be important drivers of FMT efficacy. In a small prospective study, the effect of a sterile (bacteria-free) FMT was tested in rCDI patients [99]. Although only five patients were included, all patients had resolution of their CDI-associated diarrhea. Interestingly, shifts in viral and bacterial composition towards the donor’s microbiota profile were observed. Another prospective study observed highly individualized virus colonization patterns depending on specific donor-recipient pairings [100]. The intestinal microbiome is a complex ecosystem with many yet to be identified components likely to affect human metabolism.

In addition, there is a significant knowledge gap in the link between the (small) intestinal microbiota and disease development and progression in humans. This is in large part because the accessible, fecal microbiome is usually used to analyze the microbiome composition and associate with the disease of interest (fecal bias). The small intestinal microbiome differs significantly from the fecal microbiome [101]. Together with the fact that the small intestine plays a major role in human metabolism and disease development, it is critical to develop strategies to sample small intestinal microbiome. In line, nasoduodenal administration of FMT exposes the upper GI to a lower GI/fecal microbiome. This might be a potential drawback for diseases where the upper GI microbiota or the mucosal microbiota is the main culprit. Future research needs to investigate whether and to what extent FMT is capable of modifying the upper and mucosal microbiota.

In conclusion, FMT is a promising treatment strategy for many microbiota-related indications. However, with exception of rCDI, FMT is still experimental and should not be offered as treatment option outside of a research setting. More controlled trials are needed to assess the potential benefit of FMT compared to or in addition to standard therapy.

9. Outstanding questions

FMT remains an unstandardized procedure and the optimal location of delivery and ‘dose’ of FMT to treat specific microbiota-mediated diseases remain largely unknown. Some studies show a specific microbiota profile is more effective in treating disease, while others show the microbiota profile of the recipient is predictive for the outcome of the FMT. For treating rCDI, the above appears less relevant, as high effectiveness rates are observed regardless of the route, dose, processing or donor. However, FMT as a treatment for other disease comes with a smaller effect size along with a larger group of nonresponders. Further optimization and personalization of the FMT strategy might improve the outcome in diseases beyond CDI.

The gut microbiota remains a complex ecosystem with lot of unknowns and therefore, future research should focus more on other key players beside bacteria. In addition, there is a significant difference in microbiota composition throughout the GI tract and the role of each section in human metabolism and disease development is hardly understood. Therefore, it is critical to develop strategies to sample the microbiome throughout the GI tract. In line, future research needs to investigate whether and to what extent FMT is capable of modifying the upper and mucosal microbiota.

Funding sources

K. Wortelboer is supported by a Novo Nordisk Foundation, Denmark CAMIT grant 2018. M. Nieuwdorp is supported by a ZONMW-VIDI, Netherlands grant 2013 [016.146.327] and a grant from the Dutch Heart Foundation, Netherlands, CVON IN CONTROL. H. Herrema is supported by a Le Ducq consortium, France grant 17CVD01. None of the funding bodies had any role in writing of the manuscript of selection of the literature.

Declaration of interests

M. Nieuwdorp is on the scientific advisory board of Caelus Health, the Netherlands. The remaining authors have nothing to disclose.

Author contributions

K. Wortelboer performed the literature search, wrote and corrected the article and made the figs. H. Herrema and M. Nieuwdorp critically reviewed and corrected the manuscript.
Search strategy and selection criteria

Embase, Web of Science and Pubmed were searched in December 2018 for articles using the search term “Fecal Microbiota Transplantation”, which resulted in 2027, 1581 and 1414 articles respectively. Duplicates were merged. Articles on clinical trials, systematic reviews and meta-analyses, written in English and published before 1 January 2014 were included. To identify additional relevant studies, reference lists were manually searched. In addition, we searched ClinicalTrials.gov for new and ongoing trials with FMT for indications other than CDI using the search term “[disease]” in combination with “FMT” OR “[fecal microbiota transplantation].

Acknowledgements

None.

References

[1] Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007 Oct 18;449(7164):804–10.

[2] Jung Lee W, Lattimer LDN, Stephen S, Borum ML, Doman DB. Fecal microbiota transplantation: a review of emerging indications beyond relapsing clostridium difficile toxin colitis. Gastroenterol Hepatol (N Y) 2015 Jan;11(1):24–32.

[3] Dinan TG, Cryan JF. The microbiome-gut-brain axis in health and disease. Gut 2014 Jun;63(6):782–96.

[4] Van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, De Vos WM, et al. Fecal microbiota transplantation for recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 2013;310(12):1319–25.

[5] Wang H, Cui B, Li Q, Ding X, Li P, Zhang T, et al. The safety of fecal microbiota transplantation for treatment of recurrent Clostridium difficile infection. Gastroenterol Hepatol (N Y) 2017;33(7):527–37.

[6] Cani PD. Gut microbiota-at the intersection of everything? Nat Rev Gastroenterol Hepatol 2014 Jan;11(1):25–32.

[7] Scheithauer TPM, Dallinga-Thie GM, de Vos WM, Nieuwdorp M, van Raalte DH. Colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 2017;318(20):2095–103.

[8] Janssen IJH, Antiga PS, Coenye T, Maes H. Fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection: a randomized controlled trial. PLoS One 2016;11(12):e0163291.

[9] Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal transplantation for recurrent Clostridium difficile infection: a randomized controlled trial. Ann Intern Med 2016 Nov;165(9):609–16.

[10] Camacho-Ortiz A, Gutierrez-Delgado EM, Garcia-Mazcorro JF, Mendoza-Olazaran S, Martinez-Melendez A, Palau-Davila L, et al. Randomized clinical trial to evaluate the effect of fecal microbiota transplantation for primary Clostridium difficile infection. N Engl J Med 2016 Jun;374(28):2535–46.

[11] Camacho-Ortiz A, Gutierrez-Delgado EM, Garcia-Mazcorro JF, Mendoza-Olazaran S, Martinez-Melendez A, Palau-Davila L, et al. Randomized clinical trial to evaluate the effect of fecal microbiota transplantation for primary Clostridium difficile infection in ileal microbiota. PLoS One 2017;12(12):e0189768.

[12] Khan MY, Dirweesh A, Khurshid S, Ford AC. Fecal microbiota transplantation for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2018 Nov;30(11):1309–17.

[13] Moayeddini P, Yuan Y, Baharit H, Ford AC. Fecal microbiota transplantation for “em-Clostridium difficile” versus “em-associated diarrhea”: a systematic review and meta-analysis controlled clinical trial. PLoS One 2017;12(7):e0181727.

[14] Janiero G, Maida M, Barisic J, Simonelli C, Hold G, Ventimiglia M, et al. Effect of different fecal microbiota transplantation protocols for Clostridium difficile infection: a systematic review and meta-analysis. United Eur Gastroenterol J 2018 Jun;6(6):1222–34.

[15] Lapointe-Shaw L, Tran KL, Coyte PC, Hancock-Howard RL, Powsij P, Poutman SN, et al. Cost-effectiveness analysis of six strategies to treat recurrent Clostridium difficile infection. PLoS One 2014;9(12):e115631.

[16] Varier RJ, Bilija E, Smith KJ, Roberts MS, Kyle Jensen M, Lalef J. Cost-effectiveness analysis of fecal microbiota transplantation to standard-of-care treatment for recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol 2015 Apr;36(4):438–44.

[17] Surawicz CM, Brandt LJ, Binicin DC, Asaithakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2012 Nov;108(4):785–88 [quiz 789].

[18] Taconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. ESCMID guidelines for the management of the infection control measures to prevent transmission of multidrug-resistant gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 2014 Jan;20(Suppl 1):1–55.

[19] Rossen NG, Fuentes S, van der Spek M, Tijssen JG, Hartman JHA, Duffuor A, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 2015 Jul;149(1):114–8 [e4].

[20] Garrett WS, Gallinai C, Yatsunenko T, Michaud M, Dubois A, Delaney ML, et al. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe 2010 Sep 16;8(3):292–301.

[21] Paramsothy S, Khurshid S, Ford AC. Fecal microbiota transplantation for recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 2017;318(1):51–7.

[22] Paramsothy S, Nielsen MR, Taimuru-Smart E, Dooley O, O’Boyle J, Zhao J, et al. Randomised controlled trial: faecal microbiota transplantation by colonoscopy vs. oral vancomycin for the treatment of recurrent clostridium difficile infection. Gastroenterology 2019 Apr;156(5):1324–30.

[23] Li Y-T, Cai H-F, Wang Z-H, XU J, Fang J-Y. Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for clostridium difficile infection. Aliment Pharmacol Ther 2014;39(10):1003–32.

[24] Roncon A, Casalini E, Grazzini S, Giusarb D, Zanolla F, Roig J-M, et al. Fecal microbiota transplantation is superior to placebo in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2011;34(11):1197–208.

[25] Deng H, Liu L, Chen J, Wang S, Wang J, Wu J, et al. Randomised controlled trial: faecal microbiota transplantation for recurrent Clostridium difficile infection in patients with mild-moderately active ulcerative colitis randomised controlled trial. Gastroenterology 2015 Jul;149:102–9 [e6].

[26] Paramsothy S, Kann M, Kauschou NK, Walsh AJ, van den Bogaerde J, Samuel D, et al. Multidonor intestinal microbiota transplantation for active ulcerative colitis: a randomized placebo-controlled trial. Lancet 2013 Mar;381(9875):1218–28 [London, England].

[27] Costello SP, Waters O, Bryant RV, Katsikeros R, Makanyanga J, Schoeman M, et al. Short duration, low intensity, pooled fecal microbiota transplantation induces remission in patients with mild-moderate ulcerative colitis: a randomized controlled trial. Gastroenterology 2017;152(5):5188–95.

[28] Frykman B, Catich A, Nicholson MR, Towner-Smith EE, Zuckler JF, Dominguez-Doyle G, Beaulieu DB, et al. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev 2018 Nov;11:CD012774.

[29] Speer J, Cchin S, Kann M, Deshpande NH, Alves de Barros R, Swift E, et al. Safety and efficacy of fecal microbiota transplantation for patients with ulcerative colitis. Gut Microbiol 2019 Apr;11:CD012774.

[30] Wang H, Cui B, Xi L, Zhu J, Cui J, Lu X, et al. Multiple fecal microbiota transplants induce and maintain clinical remission in Crohn’s disease complicated with inflammatory mass. Sci Rep 2017 Jul;7(1):4753.

[31] Li P, Zhang T, Xiao Y, Tian L, Cui J, B, et al. Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for ulcerative colitis. App Med Res 2019 May;8(1):44–50.

[32] Wang H, Cui B, Li Q, Ding X, Li P, Zhang T, et al. The safety of fecal microbiota transplantation for Crohn’s disease: findings from a long-term study. Adv Ther 2018 Nov;35(11):1935–44.

[33] Mappi T, Lied GA, Signore DA, El-Salhy M, Hov JR, Gilja OH, et al. The kinetics of gut microbiota community composition in patients with irritable bowel syndrome following fecal microbiota transplantation. PLoS One 2018;13(11):e0219409.

[34] Rodrigo-Janero BK, Vicario M, Alonso-Cotoner C, Pascua-Garcia R, Santos A. A review of the microbiota and irritable bowel syndrome: future in therapies. Adv Ther 2018 Mar;35(3):289–310.
Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, et al. Fecal microbiota transplant.

Zhou D, Pan Q, Shen F, Cao H-X, Ding W-J, Chen Y-W, et al. Total fecal microbiota transplant.

Hu X-F, Zhang W-Y, Wen Q, Chen W-J, Wang Z-M, Chen J, et al. Fecal microbiota transplant.

Smits LP, Kootte RS, Levin E, Prodan A, Fuentes S, Zoetendal EG, et al. Effect of vegan diet on the gut microbiota.

de Groot PF, Frissen MN, de Clercq NC, Nieuwdorp M. Fecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomized, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol 2018 Jan;3(1):17–24.

Halkier SI, Christensen AH, Lo BZS, Browne PD, Gunther S, Hansen UH, et al. Fecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a double-blind, placebo-controlled study. Gut 2018 Dec;67(12):2107–15.

Tian H, Ge X, Nie Y, Yang L, Ding C, McFarland LV, et al. Fecal microbiota transplantation in patients with slow transit constipation: a randomized, clinical trial. PLoS One 2017 Dec;12(12):e0181481–6.

Ding C, Fang W, Gu L, Tian H, Ge X, Gong J, et al. Outcomes and prognostic factors of fecal microbiota transplantation in patients with slow transit constipation: results from a prospective study with long-term follow-up. Gastroenterol Rep 2018 May 6;6(2):210–7.

Zhang X, Tian H, Gu L, Nie Y, Ding C, Ge X, et al. Long-term follow-up of the effects of fecal microbiota transplantation in combination with soluble dietary fiber as a therapeutic regimen in slow transit constipation. Sci China Life Sci 2018 Jul;61(7):779–86.

Gu L, Ding C, Tian H, Yang B, Zhang X, Hua Y, et al. Serial frozen fecal microbiota transplantation in the treatment of chronic intestinal pseudo-obstruction: a preliminary study. J Neurogastroenterol Motil 2017 Apr;23(2):289–97.

Singh R, van Nood E, Nieuwdorp M, van Dam B, Ten Berge JM, Goeirings SE, et al. Donor feces infusion for eradication of extended spectrum beta-lactamase producing Escherichia coli in a patient with end stage renal disease. Clin Microbiol Infect 2014 Nov;20(11):1097–8.

Smits L, de Groot PF, Frissen MN, de Clercq NC, Nieuwdorp M, et al. Fecal microbiota transplantation against intestinal colonization by extended spectrum beta-lactamase producing Enterobacteriaceae: a proof of principle study. BMC Gastroenterol 2018 Nov;18(1):190–7.

Dinh A, Fessi H, Duran C, Batista R, Michelon H, Bouchand F, et al. Clearance of gut microbiota from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology 2017 Dec;66(6):1727

Huttner BD, de Lastours V, Wassenberg M, Maharshak N, Mauris A, Galperine T, et al. Increased gut microbiota diversity in patients with ulcerative colitis. Sci Rep 2017 May;7(1):1529.

Bilinski J, Grzesiowski P, Sorensen N, Madry K, Muszynski J, Robak K, et al. Fecal microbiota transplantation to eradicate vancomycin-resistant enterococci colonization in patients with blood disorders inhibits gut colonization with antibiotic-resistant bacteria: results of a prospective, single-center study. BMC Infect Dis 2018 Aug;18(1):219–6.

Davido B, Batista R, Fessi H, Michelon H, Escaut L, Lawrence C, et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood 2016 Oct;128(16):2083–8.

Qi X, Li X, Zhao Y, Wu X, Chen F, Ma X, et al. Treating steroid refractory intestinal acute graft-versus-host disease with fecal microbiota transplantation: a pilot study. Front Immunol 2018;9:2195.

Spindelbock W, Schulte E, Ulh B, Kashofer K, Aigelsreiter A, Zinke-Cerwenka W, et al. Repeated fecal microbiota transplantations attenuate diarrhea and lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft-versus-host disease. Haematologica 2017 May;102(5):e210–3.

DeFilippis Z, Peled JL, Li S, Mahabumenong J, Dagher Z, Slingerland AE, et al. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv 2018 Apr;2(7):745–53.

Bousri B, Mantami R, Haykes C, Yang Y-X. Recurrent antibiotic exposure may promote cancer formation—another step in understanding the role of the human microbiome? Eur J Cancer 2015 Nov;51(17):2655–64.

Dai Z, Zhang J, Wu Q, Chen L, Ji J, Wang L, et al. The role of microbiota in the development of colorectal cancer. Int J Cancer 2019 Nov 26. https://doi.org/10.1002/ijc.32017.

Wong SH, Zhao L, Zhang X, Nakagawa G, Han J, Wu W, et al. Gavage of fecal samples from patients with colorectal cancer promotes targeted cancer cell angiogenesis in germ-free and conventional mice. Oncotarget 2017 Dec;8(53):84460–70.

Rouby B, Le Chatelier E, Deroza L, Duong CPM, Alou MT, Dailiere R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018 Jan 26;359(6371):91–7.

Wang Y, Wiersinoski DH, Helman BA, Gopalakrishnan V, Choi K, DuPont HL, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 2018 Dec;24(12):1904–8.

Wardill HR, Secombe KR, Bryant RV, Hazenberg MD, Costello SP. Adjunctive fecal microbiota transplantation in supportive oncology: emerging indications and considerations in immunocompromised patients. EBioMedicine 2019 Mar 30 https://www.ncbi.nlm.nih.gov/pubmed/30940601. (pii: 52352–3964;19. 30215–4).

Weil Y, Yang J, Wang J, Yang Y, Huang J, Gong H, et al. Successful treatment with fecal microbiota transplantation in patients with multiple organ dysfunction syndrome requiring re-transplantation. Chin J Gastroenterol 2018 Feb;16(1):33.

Fang S, Kraft CS, Dhere T, Srinivasan J, Begley B, Weinstein D, et al. Successful treatment of chronic Pouchitis utilizing fecal microbiota transplantation (FMT): a case report. Int J Colorectal Dis 2016 May;31(5):1033–4.

van Beurden YH, van Gils T, van Gils NA, Kassam Z, Mulder CJ, Aapicio-Pages N, Serendipity in refractory celiac disease: full recovery of duodenal villi and clinical symptoms after fecal microbiota transfer. J Gastrointestin Liver Dis 2016 Sep;25(3):385–8.

Hirsch BE, Sarayna N, Pookh E, Schwartz BM, Epstein ME, Hoon G. Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect Dis 2015 Nov;15(1):1–9.

Allergetti JR, Fischer M, Sagi SV, Bohm ME, Fadda HM, Ramalan SR, et al. Fecal microbiota transplantation can eradicate Clostridium difficile versus gastric delivery in its current Clostridium difficile infection: a comparative cohort analysis of high and low dose. Dig Dis Sci 2019 Jun;64(6):1672–8.

Bari J, Auro F, Murlin W, Whiteson KL, Erb ML, Polgano J, et al. Bacteriophage ad- hesion to mucous provides a shield against fecal-derived immunity. Proc Natl Acad Sci U S A 2013 Jan 21;110(26):10771–6.
Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA, et al. Efficacy of sterile fecal filtrate transfer for treating patients with *Clostridium difficile* infection. *Gastroenterology*. 2016/11/22. 2017;152(4):799–811.(e7).

Draper LA, Ryan FJ, Smith MK, Jalanka J, Mattila E, Arkkila PA, et al. Long-term colonisation with donor bacteriophages following successful faecal microbial transplantation. *Microbiome* 2018;6(1):220–9.

Zmora N, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, Bashirades S, et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. *Cell* 2018;174(6):1388–405 (e21).

Smits LP, Bouter KEC, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. *Gastroenterology* 2013 Nov;145(5):946–53.

Cammarota G, Ianiro G, Tilg H, Rajilic-Stojanovic M, Kump P, Satokari R, et al. European consensus conference on faecal microbiota transplantation in clinical practice. *Gut* 2017 Apr;66(4):569–80.